Pulse Biosciences启动Npulse™心脏导管系统治疗房颤的关键临床研究,首例患者已入组

美股速递
Apr 07

Pulse Biosciences(纳斯达克代码:PLSE)近日宣布,其针对房颤治疗的Npulse™心脏导管系统关键临床研究(Nanopulse-Af Ide)已完成首批患者入组。该研究旨在评估该系统在治疗心房颤动方面的安全性和有效性,标志着公司在该领域的研发迈入新阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10